High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

DISEASE CHARACTERISTICS: Histologically diagnosed: Acute myeloid leukemia in first, second, or third complete remission or first or second early relapse Acute lymphoblastic leukemia in first, second, or third complete remission or first or second early relapse Hodgkin's lymphoma in second or third remission or first, second, or third relapse, or refractory Non-Hodgkin's lymphoma in second or third remission or first, second, or third relapse, or refractory Multiple myeloma and plasma cell leukemia in second or third remission or first, second, or third relapse, or refractory Myelodysplastic syndrome deemed suitable for allogeneic bone marrow transplantation No symptoms or signs of CNS involvement and CNS is disease free on lumbar puncture and brain CT scan No active meningeal cancer PATIENT CHARACTERISTICS: Age: 4 to 55 (4 to 60 if donor is identical twin) Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: SGOT/SGPT less than 3 times normal Bilirubin less than 2.0 mg/dL Renal: Creatinine less than 2.1 mg/dL Creatinine clearance at least 60 mL/min (no greater than 1.5 times normal for children under 40 kg) Cardiovascular: No uncontrolled hypertension No uncontrolled congestive heart failure No active angina pectoris requiring nitrates At least 6 months since prior myocardial infarction No major ventricular arrhythmia Left ventricular ejection fraction at least 45% on MUGA Pulmonary: No severe or symptomatic restrictive or obstructive lung disease FEV_1 greater than 50% of predicted DLCO greater than 50% of predicted Neurologic: No severe central or peripheral neurologic abnormality Other: Must have HLA-A,B,C,D/DR identical sibling age 4 to 65, in good health No insulin-dependent diabetes mellitus No major thyroid or major adrenal dysfunction No active infection No other active malignancy Not pregnant HIV negative HTLV-I and HTLV-II negative PRIOR CONCURRENT THERAPY: Biologic therapy: No excessive anthracycline exposure, unless endomyocardial biopsy shows less than grade 2 drug effect and cardiac scan shows at least 50% ejection fraction At least 1 year since prior autologous bone marrow or peripheral blood progenitor cell transplant or allogeneic bone marrow transplant Chemotherapy: At least 3 weeks since prior chemotherapy No prior excessive carmustine and bleomycin Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy Surgery: Not specified Other: No concurrent nitroglycerin for angina pectoris No concurrent anti-arrhythmic drugs for major ventricular dysrhythmias